Loading clinical trials...
Loading clinical trials...
OPC-1085EL ophthalmic solution, carteolol long-acting ophthalmic solution or latanoprost ophthalmic solution are administered once daily for 7 days and the effect on the blood concentration of carteol...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Otsuka Pharmaceutical Co., Ltd.
NCT07539675 · Primary Angle-Closure Glaucoma
NCT06289491 · Glaucoma, Glaucoma, Open-Angle
NCT07496957 · GLAUCOMA 1, OPEN ANGLE, D (Disorder)
NCT04354545 · Glaucoma, Ocular Surface Disease
NCT07455786 · Glaucoma
Kansai Region
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions